BMJ Open

Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza in 2015–2016: a hospital-based test-negative case–control study in Lithuania

Monika Kuliese,[1] Ligita Jancoriene,[2,3] Rita Grimalauskaite,[4] Birute Zablockiene,[2,3] Gyte Damuleviciene,[4] Daiva Velyvyte,[1] Vita Lesauskaite,[4] Arvydas Ambrozaitis,[2,3] Aukse Mickiene,[1] Giedre Gefenaite[1]

[1]Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
[2]Clinic of Infectious, Chest Diseases, Dermatovenerology and Allergology, Vilnius University Faculty of Medicine, Vilnius, Lithuania
[3]Centre of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
[4]Department of Geriatrics, Lithuanian University of Health Sciences, Kaunas, Lithuania

Correspondence to
Dr Monika Kuliese;
m.kuliese@gmail.com

ABSTRACT

Objective A case–control study was conducted to assess seasonal influenza vaccine effectiveness (SIVE) during the 2015–2016 influenza season.

Methods A study was performed in three departments in Lithuania between 1 December 2015 and 1 May 2016. Data on demographic and clinical characteristics including influenza vaccination status were collected from the patients recommended to receive the seasonal influenza vaccine. Influenza virus infection was confirmed by multiplex reverse transcription polymerase chain reaction (RT-PCR) .

Results Ninety-one (56.4%) of the 163 included subjects were ≥65 years old. Fifteen (9.2%) subjects were vaccinated against influenza at least 2 weeks before the onset of influenza symptoms, 12 of them were ≥65 years old. Of the 72 (44.2%) influenza virus positive cases, 65 (39.9%) were confirmed with influenza A (including 50 cases of influenza A(H1N1)pdm09), eight (4.9%) were confirmed with influenza B and one was a co-infection. Unadjusted SIVE against any influenza, influenza type A and influenza A(H1N1)pdm09 was 57% (95% CI −41% to 87%), 52% (95% CI −57% to 85%) and 70% (95% CI −43% to 94%) respectively.

Conclusion Although SIVE estimates were not statistically significant the point estimates suggest moderate effectiveness against influenza type A.

INTRODUCTION

Influenza is a highly contagious viral airborne disease that in the northern hemisphere typically occurs during the winter months.[1] Annual influenza epidemics result in high morbidity (three to five million cases of severe illness) and significant mortality rates (250 000–500 000 deaths) worldwide.[2] In addition, for people with chronic underlying medical conditions and those of 65 years old and older influenza is associated with significant adverse health outcomes,[3–5] such as influenza-related hospitalisations and deaths.[6 7]

Strengths and limitations of this study

► This test-negative case–control study aimed to estimate seasonal influenza vaccine effectiveness (SIVE) against laboratory-confirmed influenza virus infection in patients admitted to the hospital due to severe acute respiratory infection in Lithuania during the 2015–2016 season.

► The selection bias was reduced by including the patients into the study before the laboratory result of influenza virus infection status was known; the outcome bias was further reduced by using a very sensitive influenza detection method; the exposure misclassification was very unlikely, because the exposure status was verified with the general practitioner records.

► The low precision of the SIVE estimates was due to low number of (vaccinated) patients.

► The obtained estimates are likely to be a reasonable indication of SIVE during the 2015–2016 season.

The most effective way to prevent potentially severe influenza complications is vaccination.[8 9] Annual influenza immunisation is recommended for the most vulnerable groups, such as adults aged ≥65 years and people with co-morbidities.[10] However, the evidence base for this recommendation is weak, and except for a few randomised control trials, is based on the results of observational studies.[11 12] The lack of laboratory confirmation of influenza infection and the assessment of influenza vaccination effectiveness against non-specific outcomes are the major limitations of the majority of the existing observational studies. Relatively recently, the test-negative case–control studies have been introduced to assess seasonal influenza vaccine effectiveness (SIVE), and despite some limitations, they are currently considered to be the most accurate and efficient way to monitor SIVE.[13]

BMJ

Due to frequent change in the circulating influenza strains, SIVE should be monitored on a routine basis.[14] This is useful in guiding the influenza prevention and informing the treatment strategies during the influenza epidemics and it could also help when making a decision on the next season's influenza vaccine content.[11] Furthermore, due to different timing and spread of the influenza viruses across Europe,[15] SIVE estimates derived from different geographical areas are of particular interest and of great relevance as well.

In Lithuania, adults≥65 years of age, pregnant women, people with underlying medical conditions and healthcare workers are eligible to receive influenza vaccination free of charge. The vaccines used for the immunisation of the risk groups in Lithuania are trivalent influenza vaccines. For the 2015–2016 influenza season, one dose of a subunit influenza vaccine Influvac (BGP Products, HOOFD-DORP, The Netherlands) was used.[16] According to the recommendations of the WHO,[17] this vaccine contained three influenza virus strains, A/California/7/2009 (H1N1)-like strain, A/Switzerland/9715293/2013 (H3N2)-like strain and B/Phuket/3073/2013 (belonging to B/Yamagata lineage). However, vaccination coverage of the risk groups in Lithuania is extremely low and calls for more evidence of protection to help promoting vaccination among risk groups.

The objective of this study was to measure SIVE against laboratory-confirmed influenza in patients admitted to hospital due to severe acute respiratory infection (SARI) in Lithuania in 2015–2016.

METHODS

Study population and recruitment procedure

A test-negative case–control study was conducted between 1 December 2015 and 1 May 2016. The subjects were recruited from three participating sites: Centre of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; the Department of Infectious Diseases and the Department of Geriatrics of Lithuanian University of Health Sciences, Kaunas. The study population consisted of 18 years and older individuals with underlying medical conditions, healthy ≥65 years old individuals and pregnant women living in the community, who were admitted to one of the participating sites due to SARI with no contraindication for influenza vaccination, that is, allergies to influenza vaccine and other adverse events to vaccinations in the past. Patients were eligible to be included in the study when they were hospitalised for at least 24 hours, but not longer than 48 hours, had a swab taken ≤7 days after self-reported disease onset, did not test positive and were not hospitalised for any influenza virus in the current season before the inclusion, and were suffering from SARI with at least one of the systemic symptoms (fever, malaise, headache and myalgia) or deterioration of general condition or deterioration of functional status, and at least one of the respiratory symptoms (cough, sore throat and shortness of breath). Patients

were not eligible to be included in the study when they were institutionalised, unwilling to participate, not able to communicate, not able and/or willing to give written informed consent (IC). Eligible patients were asked to provide one throat and one nose swab specimen for influenza testing by the multiplex RT-PCR. As data from shedding studies propose that influenza virus detection decreases after 7 days, recruitment was limited to patients who were swabbed not more than 7 days after onset of the symptoms.[18] Swabbing was done after the information on demographic and clinical characteristics was collected from the medical history and patient self-report.

Outcomes

The outcome was laboratory-confirmed influenza virus infection in patients admitted to hospital for SARI. SARI patients positive for influenza A(H1N1)pdm09, A(H3N2), non-typed A or influenza B viruses were considered as cases. The control group consisted of patients who were negative for any influenza virus infection.

Exposure

The exposure of interest was vaccination with trivalent seasonal influenza vaccine, available in Lithuania during 2015–2016 influenza season.[16] Subjects were considered as vaccinated if their vaccination status was confirmed by their general practitioner (GP) records, and the vaccination occurred more than 14 days before disease onset or more than 14 days before being selected as controls, who also had SARI onset. Otherwise, they were considered as unvaccinated.

Covariates

Information about age, sex, antiviral drug use during current hospitalisation, transfer to the intensive care unit, hospitalisations due to disease exacerbation in the last 12 months, length of hospitalisation and occurrence of underlying medical conditions (cardiovascular, respiratory, renal, rheumatological, endocrine diseases and diabetes, haematological and non-haematological cancer, immunodeficiency and transplantation, dementia, stroke, anaemia (according to the International Classification of Diseases 10) were collected from the medical records (online supplementary appendix 1). Socioeconomic status (education, occupation, income per household member), living in urban or rural areas, smoking status, body mass index (BMI), obesity (BMI≥30), number of hospitalisations and number of visits to GP due to the underlying medical conditions (but not repeated prescriptions) in the preceding year, and Barthel scores to assess dependence in activities of daily living before the hospitalisation were collected from the self-reports.

Laboratory analysis

The nasal and throat swabs were kept in the fridge at the ward at +4°C up to 72 hours. During this time, the samples were transported to the National Public Health Laboratory (NPHL). If the samples were not transferred to the NPHL within 72 hours, they were frozen at −70°C.

When transported to the NPHL the samples were kept in −70°C while analysed. Viral RNA from the samples was isolated using an automatic magnetic particle method based on the Centre for Disease Control and Prevention (CDC) recommendations,[19] with CDC Influenza Virus RT-PCR Influenza A/B Typing Panel. For the detection on influenza and other respiratory pathogens (coronavirus, respiratory syncytial virus (RSV), adenovirus, metapneumovirus, parainfluenza virus and rhinovirus) Anyplex IIRV16 Detection (V1.1) (Seegene, Seoul, Korea) kit was used. After targeting the matrix gene of influenza A or B the samples were subtyped using multiple primers: CDC Influenza Virus RT-PCR Influenza A(H1/H3/H1pdm09) Subtyping Panel and B/Vic and B/Yam (CDC Influenza B Lineage Genotyping panel). If influenza A subtyping with these primer kits was unsuccessful, the samples were subtyped using A/H5 (CDC Influenza Virus RT-PCR Influenza A/H5 (Asian Lineage) Subtyping Panel) or A/H7 (CDC Influenza A/H7 (Eurasian Lineage) Assay) primer kits.

Sample size calculation

Based on our pilot study,[20] and influenza vaccination rates among the risk groups in Lithuania, we assumed the vaccination rates among the cases and controls of 2% and 15% respectively. To achieve the statistical power of 80% with a confidence level of 95%, the required sample size was 170 subjects. The sample size was estimated for the total sample only.

Statistical analysis

The demographic and clinical characteristic of cases and controls were compared by using Fisher's chi-square test and Student's t-test. The analysis was adjusted for confounding when the variables were associated with both the outcome and the vaccination at alpha level of 10%. SIVE and its 95% confidence interval (95% CI) was estimated by using the formula (1–OR)*100%.

Ethical considerations

The study was conducted in accordance with the Lithuania legislation and the Declaration of Helsinki. Kaunas Regional Biomedical Research Ethics Committee (Kaunas, Lithuania) and State Data Protection Inspectorate approvals P2-158200-04-476-138/2012, dated 23 February 2016 and 2R-372(2.6-1.) dated 21 January 2016 were received respectively. The written IC was obtained from the study subjects.

RESULTS

Overall, 1003 patients were screened and 180 met the inclusion criteria, of which 163 (91%) subjects gave an IC and were included into the study. Ninety-one (55.8%) subjects were negative for any influenza virus infection, 72 (44.2%) subjects tested positive for influenza virus infection. Sixty-five subjects (39.9%) were confirmed with influenza virus A infection, including 50 cases of influenza

A(H1N1)pdm09. The subtyping was inconclusive for 15 specimens of influenza type A. There were eight (4.9%) cases with influenza B virus infection (seven B/Victoria; one unsubtyped) and one (0.6%) had a co-infection with unsubtyped influenza virus A and B/Victoria. Eighty-four (91.3%) patients were swabbed within 4 days of antiviral administration, of which 32 (34.8%) were administered antivirals before or on the day of swabbing and 39 (42.4%) patients were swabbed 1 day after the administration of antivirals. In addition to influenza, seven subjects were co-infected: two with adenovirus (2.8%), one with coronavirus (1.4%), two with metapneumovirus (2.8%) and two with RSV (2.8%). Other respiratory pathogens isolated from the study participants (n=25) were RSV (6, 3.7%), adenovirus (5, 3.1%), metapneumovirus (5, 3.1%), rhinovirus (6, 3.7%), coronavirus (2, 2.3%) and parainfluenza (1, 0.6%).

The observed influenza peak in our study occurred in week 6 (figure 1), which overlapped with the nationally detected influenza season's peak in Lithuania in 2015–2016 (figure 2).

The average age of the influenza cases was significantly lower than the controls (59 vs 67 years old). Influenza cases had significantly less underlying medical conditions, such as cardiovascular and lung diseases, were less often hospitalised during the last 12 months due to the exacerbations of the underlying illnesses, and were prescribed oseltamivir twice more often (table 1).

Fifteen (9.1%) subjects were vaccinated against influenza in the 2015–2016 season, of which 12 were ≥65 years old (table 1). All vaccinations occurred more than 14 days before the onset of SARI. Vaccinated individuals were older, more likely to have received the seasonal influenza vaccine during the previous season and had slightly shorter length of hospitalisation (table 1).

Influenza cases appeared to have more cough and less shortness of breath and deterioration of general condition than the controls (table 2).

In the total sample, five out of 163 patients died during the hospitalisation, of which 4/72 (5.6%) within the influenza confirmed cases (including one vaccinated death), and 1/91 (1.1%) within the controls (ceased subject not vaccinated).

Vaccine effectiveness analysis

Unadjusted SIVE point estimates against any influenza, influenza type A and influenza A(H1N1)pdm09 were 57% (95% CI −41% to 87%), 52% (95% CI −57% to 85%) and 70% (95% CI −43% to 94%) respectively, however they were not statistically significant (table 3).

As age was associated with both vaccination status and the outcome, we performed SIVE analysis by age group (18–64 and ≥65 years old). In the stratified by age analysis, the SIVE point estimate for any influenza and influenza type A for the subjects of 18–64 years old increased, while it dropped in the ≥65 years old subjects (table 3). This was not the case for the SIVE against A(H1N1)pdm09. None of the results in the stratified analysis were statistically

**Figure 1** Number of specimens for influenza (sub)type during 2015–2016 influenza season in the study.

significant. Due to low statistical power, the analysis to estimate SIVE against influenza type B/Victoria was not performed. The sensitivity analysis with a scenario when 0 vaccinated influenza B cases were replaced with one was used.[21] However, the unadjusted OR resulted in 1.04, indicating no SIVE (95% CI 0.02 to 9.47).

DISCUSSION

This study aimed to estimate SIVE against laboratory-confirmed influenza virus infection in patients admitted to the hospital due to SARI in Lithuania during the 2015–2016 season.

Our estimates indicated vaccine effectiveness against any influenza, influenza type A and influenza A(H1N1) pdm09 of 57%, 52% and 70% respectively, but none of them were statistically significant. After stratifying by age SIVE point estimates against any influenza and influenza type A slightly increased in the 18–64 years old individuals, and decreased in those ≥65 years old. Due to the lack

Figure 2 Number of specimens positive for influenza (sub)type in Lithuania during 2015–2016 influenza season.

Table 1 Demographic and clinical characteristics of cases and controls and by influenza vaccination status in the total sample during the 2015–2016 influenza season

	Influenza test result					SIV in 2015–2016					
	Influenza-positive n=72 44.2%		Influenza-negative n=91 55.8%		p Value	Vaccinated n=15 9.2%		Unvaccinated n=148 90.8%		p-Value
	N	%	N	%		N	%	n	%	
Male sex	30	41.7	46	50.5	0.27	10	66.7	66	44.6	0.11
Urban	56	77.8	72	79.1	0.85	9	60.0	119	80.4	0.09
Age≥65	32	44.4	59	64.8	0.01	12	80.0	79	53.4	0.06
Age (mean, SD)	59.1	19.2	67.1	17.2	0.01	72.9	10.1	62.6	18.9	0.04
Education										
High (college, university)	29	42.0	36	39.6	0.81	7	46.7	58	40.0	0.78
Low (primary, unfinished, secondary, professional)	40	58.0	55	60.4		8	53.3	87	60.0	
Occupation										
Intellectual or/and physical work	17	23.6	19	20.9	0.71	1	6.7	35	23.6	0.19
Retired/handicapped/jobless	55	76.4	72	79.1		14	93.3	113	76.4	
Income per household member										
<€600	57	91.9	75	97.4	0.24	13	92.9	119	95.2	0.53
≥€600	5	8.1	2	2.6		1	7.1	6	4.8	
Smoking										
Never	35	49.3	45	49.5	0.48	7	46.7	73	49.7	0.52
Former	23	32.4	35	38.5		7	46.7	51	34.7	
Current	13	18.3	11	12.1		1	6.7	23	15.6	
Pregnant	10	13.9	1	1.1	0.003	0	0.0	11	7.4	0.60
Chronic condition (at least 1)	60	83.3	87	95.6	0.02	13	86.7	134	90.5	0.65
At least one hospitalisation due to exacerbation of underlying conditions in the previous 12 months	13	21.7	37	42.5	0.01	7	53.8	43	32.1	0.13
At least 1 GP visit in the previous 12 months	24	34.8	35	38.9	0.62	3	21.4	56	38.6	0.26
Cardiovascular disease	34	47.2	59	64.8	0.03	10	66.7	83	56.1	0.58
Lung diseases	10	13.9	32	35.2	0.002	4	26.7	38	25.7	1.00
Endocrine diseases, diabetes	6	8.3	18	19.8	0.05	3	20.0	21	14.2	0.47
Renal diseases	5	6.9	9	9.9	0.58	1	6.7	13	8.8	1.00
Immunodeficiency and transplantations	5	6.9	1	1.1	0.09	0	0.0	6	4.1	1.00
Rheumatological diseases	2	2.8	2	2.2	1.00	0	0.0	4	2.7	1.00
Dementia, strokes	11	15.3	26	28.6	0.06	5	33.3	32	21.6	0.33
Haematological cancer	4	5.6	4	4.4	0.73	1	6.7	7	4.7	0.55

Continued

Table 1 Continued

| | Influenza test result | | | | | SIV in 2015–2016 | | | | |
| | Influenza-positive n=72 44.2% | | Influenza-negative n=91 55.8% | | p Value | Vaccinated n=15 9.2% | | Unvaccinated n=148 90.8% | | p-Value |
	N	%	N	%		N	%	n	%	
Non-haematological cancer	9	12.5	15	16.5	0.51	3	20.0	21	14.2	0.47
Anaemia, spleen	3	4.2	6	6.6	0.73	2	13.3	7	4.7	0.20
Cirrhosis	0	0	0	0	–	0	0	0	0	–
Nutritional deficiency	2	2.8	6	6.6	0.47	0	0	8	5.4	1
Obesity	18	25.0	33	36.3	0.13	2	13.3	49	33.1	0.15
BMI (mean, SD)	27.59	±5.79	28.47	±6.00	0.35	26.88	±3.58	28.21	±6.10	0.41
Antiviral use										
Oseltamivir	56	77.8	33	36.3	<0.001	8	53.3	81	54.7	1.00
Zanamivir	4	5.6	1	1.1	0.17	0	0.0	5	3.4	1.00
SIV in 2014–2015 season	2	2.9	6	6.7	0.47	6	46.2	2	1.4	≤0.001
SIV in 2015–2016 season	4	5.6	11	12.1	0.18	–	–	–	–	–
Length of hospitalisation (mean, SD)	7.5	±6.0	9.2	±6.0	0.07	9.1	±4.2	8.4	±6.2	0.04
Transfer to the intensive care unit	6	8.3	1	1.1	0.05	1	6.7	6	4.1	0.50
Deaths	4	5.6	1	1.1	0.17	1	6.7	4	2.7	0.39

BMI, body mass index; GP, general practitioner; SIV, seasonal influenza vaccination.

Table 2 Systemic and respiratory symptoms among cases and controls

	Influenza test result				
	Influenza-positive n=72 44.2%		Influenza-negative n=91 55.8%		p Value
Respiratory symptoms					
Cough	72	100.0	83	91.2	0.01
Sore throat	43	60.6	45	50.0	0.40
Shortness of breath	34	47.2	70	76.9	<0.001
Systemic symptoms					
Fever	70	97.2	82	90.2	0.11
Malaise	71	100.0	90	98.9	0.36
Myalgia	46	65.7	48	53.3	0.21
Headache	56	78.9	71	78.0	0.53
Sudden onset of symptoms	68	94.4	79	86.8	0.12
Deterioration of general condition	48	66.7	86	94.5	<0.001
Deterioration of functional status (Barthel index<100)	15	21.1	41	45.1	0.06

of precision in the subgroup analysis, these results can serve only as indicatory.

In our study, SIVE was higher than the mid-season estimates against influenza A(H1N1)pdm09 reported in the primary and hospital patient populations in Denmark (35% in ≥65 years old subjects) and in the GP patient population in the UK (49% in all age groups).[12 22] Lower point estimates (crude 26.2% and adjusted 6.2%) against the predominant A(H1N1)pdm09 were reported from multicentre European network of hospitals during the 2012–2013 influenza season.[11] **In the individual participant data meta-analysis in the community dwelling elderly**

confounder-adjusted vaccine effectiveness estimate against A(H1N1)pdm09 resulted in 53.2%.[23] During the 2013–2014 influenza season with predominant influenza A(H1N1)pdm09 in Canada an adjusted SIVE in elderly of 67% was found.[24] Due to the lack of published data reporting vaccine effectiveness in 2015–2016, SIVE comparison across countries and/or regions is still missing. In addition, in the previous study conducted by our group in a similar setting in the 2012–2013 we found 30% higher SIVE than during the 2015–2016 season.[20] It is necessary to point out that influenza A(H1N1), influenza A(H3) and influenza B cases were predominant

Table 3 Seasonal influenza vaccination effectiveness against influenza in patients hospitalised for severe acute respiratory infection during the 2015–2016 influenza season

	n vaccinated/N cases (coverage %)	n vaccinated/N controls (coverage %)	Unadjusted OR (95% CI)
Any influenza			
Total	4/72 (5.6)	11/91 (12.1)	0.43 (0.13 to 1.41)
18–64 years old	1/40 (2.5)	2/32 (6.3)	0.39 (0.03 to 4.45)
≥65 years old	3/32 (9.4)	9/59 (15.3)	0.58 (0.14 to 2.30)
Influenza A			
Total	4/65 (6.2)	11/91 (12.1)	0.48 (0.15 to 1.57)
18–64 years old	1/35 (2.9)	2/32 (6.3)	0.44 (0.04 to 5.11)
≥65 years old	3/30 (10.0)	9/59 (15.3)	0.62 (0.15 to 2.47)
Influenza A(H1N1)pdm09			
Total	2/50 (4.0)	11/91 (12.1)	0.30 (0.06 to 1.43)
18–64 years old	1/33 (3.0)	2/32 (6.3)	0.47 (0.04 to 5.44)
≥65 years old	1/17 (5.9)	9/59 (15.3)	0.35 (0.04 to 2.96)
Influenza B/Victoria			
Total*	1/7 (14.3)	11/91 (12.1)	1.04 (0.02 to 9.47)

*To be able to perform the seasonal influenza vaccination estimation 0 vaccinated influenza B cases were replaced with one in this analysis.

during the 2012–2013 season, while influenza A(H1N1) pdm09 was predominant during the season 2015–2016.

We used influenza virus negative patients as controls in our study. It has been shown that the use of different control groups (ie, negative for influenza viruses; negative for influenza viruses, but positive for other respiratory viruses; negative for both influenza and other respiratory viruses) in test-negative design case–control studies resulted in different SIVE estimates.[25–30] However, the results so far have not been consistent, and the discussion about the study designs and methodological challenges using each of the control groups is still ongoing.[26 30 31] Some differences in point estimates of SIVE when using different control groups have recently been reported, but the confidence intervals of the estimates overlapped.[30 31] Given these inconsistencies and even lower sample size when restricting the controls to only influenza negative or all respiratory viruses negative in our study, the control group of influenza virus negative patients remains a valid choice.

Seven influenza B/Victoria cases were detected in our study. Although we were not able to perform SIVE due to extremely low numbers of influenza B cases, our findings show that the circulating strain mismatched the B/Yamagata lineage virus, which was included in the 2015/2016 season's vaccine. This was confirmed by the OR of 1 when 0 vaccinated influenza B cases were replaced with one case, as well as not significant mid-season estimate of 4% found in Denmark.[12]

Five deaths occurred in our study during the 2015–2016 influenza season, of which four subjects were positive for influenza A(H1N1)pdm09. All five subjects had at least one underlying medical condition. Three of the four influenza cases were younger than 65 years. Only one (influenza positive) patient was vaccinated against influenza this season. During hospitalisation, all patients developed the unilateral or bilateral pneumonia. The main cause of death among the influenza cases was the respiratory insufficiency due to the acute respiratory distress syndrome. Such high mortality in our study sample, and especially among the influenza confirmed cases (5.6%) as compared with controls (1.1%) reflects the severity of the condition of the hospitalised population and the increased risk for severe influenza-related outcomes and calls for better influenza prevention measures for the risk groups.

The response rate in this study was very high and exceeded 90%. The selection bias was reduced by including the patients into the study before the laboratory result of influenza status was known; cases and controls were similar with regard to the demographic and clinical characteristics. The outcome bias was further reduced by using a very sensitive influenza detection method.[32] The exposure status was verified with the GP, and therefore exposure misclassification was very unlikely. That together gives us confidence that despite low sample size and low precision of the SIVE estimates, the bias in this test-negative case–control study, except

for unmeasured confounding, which we were not able to assess, is limited.[33 34]

This study has several limitations. First, the two participating university hospitals are located in two of the 10 districts in the country. However, the infectious diseases units in these hospitals are the main centres where the majority of patients with clinically suspected influenza are admitted in the Vilnius and Kaunas regions and they cover about 35% of the Lithuanian population.[35] The low precision of the SIVE estimates was partly due to low number of vaccinated patients, which would require a much higher sample size to be able to provide precise SIVE estimates. Nevertheless, we addressed the potential biases in the design and the analysis stages of the study, and at least for influenza type A the obtained estimates are likely to be a reasonable indication of SIVE during the 2015–2016 season.

In Lithuania, the vaccination coverage among the risk groups is very low. According to the Centre for Communicable Diseases and AIDS, 19.5% of the elderly population were vaccinated during the 2015–2016 influenza season, while in several other European countries the vaccination coverage among the risk groups varies from 28% in Portugal to 80.2% in Northern Ireland.[36] Different vaccination rates in the European countries that generally adopt the same recommendations might be explained by different communication activities, differences in vaccination provision systems, funding schemes, attitudes and trust in seasonal influenza vaccination recommendations. In England, for example, GPs and other providers are encouraged to contact eligible patients in September and actively invite them to attend the clinics and get vaccinated against influenza.[17 37] In Lithuania, personal invitations are usually not sent and the vaccination coverage among the healthcare workers themselves is quite low,[36] which likely influences the patients' decisions as well. The patients eligible for influenza vaccination (ie, those suffering from underlying condition, ≥65 years old, pregnant women) are usually offered and administered the vaccine if they are visiting their GP during the weeks when the vaccine is available (October–December), which limits the number of patients who would potentially be willing to get vaccinated if they were actively invited.

In addition to the routine SIVE assessments to inform influenza prevention and treatment strategies, multiple questions remain to be tackled by future studies. Multiple years are needed to investigate the role of the previous influenza infection as a potential effect modifier for the vaccine effectiveness estimates.[38] Due to absence of electronic record system, we do not have information about (laboratory-confirmed) influenza illness in the previous seasons for the same subset of patients. We are therefore not able to determine the effect of previous laboratory-confirmed influenza on SIVE. Also, bigger sample size is needed to monitor within-season waning immunity and to determine whether the timing of the influenza immunisation campaigns needs to be revised.[39]

CONCLUSIONS

Although SIVE estimates confidence intervals are broad, this study suggests moderate effectiveness against influenza type A. Even with moderate vaccine effectiveness estimates, given such high prevalence of influenza in hospitalised cases and relatively high number of deaths, there is an urgent need for adopting more effective vaccination campaign strategies in countries with low vaccination uptake rates.

REFERENCES

1. Commission of the European Communities. Council recommendation of 13 July 2009 on Seasonal Influenza vaccination. *Off J* 2009;09:1–12. *L 353, 13/7/.*
2. Rondy M, Puig-Barbera J, Launay O, *et al*. 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: pooled Analysis from a European Network of Hospitals. A pilot study.. *PLoS One* 2013:8.
3. Thompson WW, *et al*. Influenza-Associated Hospitalizations in the United States. *JAMA* 2004;292:1333–40.
4. Barnes M, Heywood AE, Mahimbo A, *et al*. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. *Heart* 2015;101:1738–47.
5. Plans-Rubió P. Prevention and control of influenza in persons with chronic obstructive pulmonary disease. *International Journal of COPD* 2007;2:41–53.
6. Bödeker B, Remschmidt C, Schmich P, *et al*. Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study. *BMC Public Health* 2015;15:618 http://bmcpublichealth.biomedcentral.com/articles/.
7. Castilla J, Guevara M, Martínez-Baz I, *et al*. Enhanced estimates of the Influenza vaccination effect in preventing mortality: a Prospective Cohort Study. *Medicine (Baltimore) [Internet]* 2015;94:e1240 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4554121&tool=pmcentrez&rendertype=abstract.
8. Veljkovic V, Paessler S, Glisic S, *et al*. Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. *Front Microbiol* 2015;6:1 http://journal.frontiersin.org/Article/.
9. Cowling BJ, Feng S, Finelli L, *et al*. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010–13, United States. *Vaccine* 2016;34:61–6 http://linkinghub.elsevier.com/retrieve/pii/S0264410X15016369.
10. World Health Organization. Weekly epidemiological record. *Wkly Epidemiol Rec* 2012;47:461–76 http://orton.catie.ac.cr/cgi-bin/wxis.exe/?IsisScript=KARDEX.xis&method=post&formato=2&cantidad=1&expresion=mfn=003687.
11. Rondy M, Launay O, Gefenaite G, *et al*. Influenza vaccine effectiveness against hospitalised influenza A (H1N1)pdm09, A (H3N2) and B: estimates from a european network of hospitals. *Euro Surveill* 2012/132015;2021011 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21011.
12. Emborg HD, Krause TG, Nielsen L, *et al*. Influenza vaccine effectiveness in adults 65 years and Older, Denmark, 2015/16 – a rapid epidemiological and virological assessment. *Eurosurveillance* 2016;21.
13. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. *Expert Rev Vaccines* 2014;13:1571–91.
14. Valenciano M, Ciancio B, Moren A. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. *Euro Surveill Bull Eur sur les Mal Transm = Eur Commun Dis Bull* 2008;13:1–8.
15. Martirosyan L, Paget WJ, Jorgensen P, *et al*. The community impact of the 2009 influenza pandemic in the WHO European Region: a comparison with Historical Seasonal data from 28 countries. *BMC Infect Dis* 2012;12:36 http://www.biomedcentral.com/1471-2334/12/36.
16. Abbott Biologicals B.VInfluvac sub-unit suspension for injection Influenza vaccine surface antigen (Inactivated) Season 2016;. [Internet]. Available from http://www.medicines.org.uk/emc/medicine/21154.
17. Organisation WH. Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza season. 2015;(February 2014):1–15 http://www.euro.who.int/__data/assets/pdf_file/0011/290954/WHO-Euro-recommendations-influenza-vaccination-2015-2016.pdf?ua=1]. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25771542&retmode=ref&cmd=prlinks%5Cnpapers3://publication/uuid/D5A5FF30-19E1-45F0-A209-809291D78F8F.
18. Suess T, Remschmidt C, Schink SB, *et al*. Comparison of shedding characteristics of Seasonal Influenza virus (Sub)Types and Influenza A(H1N1)pdm09; Germany, 2007–2011. *PLoS One* 2012;7:e51653–11.
19. CDC. CDC Protocol of realtime RT-PCR for influenza A (H1N1). *World Heal Organ* 2009;17 http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf.
20. Gefenaite G, Rahamat-Langendoen J, Ambrozaitis A, *et al*. Seasonal influenza vaccine effectiveness against influenza in 2012–2013: A hospital-based case-control study in Lithuania. *Vaccine* 2014;32:857–63.
21. Rothman KJ. Computation of exact confidence intervals for the odds ratio. *Int J Biomed Comput* 1975;6:33–9.
22. Pebody R, Warburton F, Ellis J, *et al*. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. *Euro Surveill* 2016;21.
23 Darvishian M, van den Heuvel ER, Bissielo A, *et al*. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. *Lancet Respir Med* 2017;5:200–11.
24 Skowronski DM, Chambers C, Sabaiduc S, *et al*. Integrated Sentinel Surveillance Linking Genetic, antigenic, and epidemiologic monitoring of Influenza Vaccine-Virus relatedness and Effectiveness during the 2013–2014 Influenza Season. *J Infect Dis* 2015;212:726–39.
25 Darvishian M, Dijkstra F, van Doorn E, *et al*. Influenza vaccine effectiveness in the Netherlands from 2003/2004 throug 2013/2014: the importance of circulating influenza virus types and subtypes. *Under Rev* 2017.
26 Nunes B, Machado A, Guiomar R, *et al*. Estimates of 2012/13 influenza vaccine effectiveness using the case test-negative control design with different influenza negative control groups. *Vaccine* 2014;32:4443–9.
27 Kelly H, Jacoby P, Dixon GA, a DG, *et al*. Vaccine Effectiveness against Laboratory-confirmed Influenza in healthy young children. *Pediatr Infect Dis J* 2011;30:107–11 http://www.ncbi.nlm.nih.gov/pubmed/21079528.
28 Blyth CC, Jacoby P, Effler PV, *et al*. Effectiveness of trivalent flu vaccine in healthy young children. *Pediatrics* 2014;133:e1218–e1225.
29 Puig-Barberà J, Díez-Domingo J, Arnedo-Pena A, *et al*. Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A case–case comparison, case-control study. *Vaccine* 2012;30:5714–20.
30 Sundaram ME, McClure DL, VanWormer JJ, *et al*. Influenza vaccination is not associated with detection of Noninfluenza

respiratory viruses in Seasonal studies of Influenza Vaccine Effectiveness. *Clinical Infectious Diseases* 2013;57:789–93.

31 van Doorn E, Darvishian M, Dijkstra F, *et al*. Influenza vaccine effectiveness estimates in the dutch population from 2003 to 2014: the test-negative design case-control study with different control groups. *Vaccine* 2017;35:2831–9.

32. Petric M, Comanor L, Petti CA. Role of the Laboratory in Diagnosis of Influenza during Seasonal Epidemics and Potential Pandemics. *J Infect Dis* 2006;194:S98–S110 http://www.ncbi.nlm.nih.gov/pubmed/17163396.

33 Darvishian M, Bijlsma MJ, Hak E, *et al*. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. *Lancet Infect Dis* 2014;14:1228–39.

34 Haber M, An Q, Foppa IM, *et al*. A probability model for evaluating the Bias and precision of influenza vaccine effectiveness estimates from case-control studies. *Epidemiol Infect* 2015;143:1417–26.

35 Lithuania S. Teritory and population [Internet].. 2014;6 http://db1.stat.gov.lt/statbank/selectvarval/saveselections.asp?MainTable=M3010211&PLanguage=0&TableStyle=&Buttons=&PXSId=3767&IQY=&TC=&ST=ST&rvar0=&rvar1=&rvar2=&rvar3=&rvar4=&rvar5=&rvar6=&rvar7=&rvar8=&rvar9=&rvar10=&rvar11=&rvar12=&rvar13=&rvar14=.

36 Mereckiene J, Cotter S, O'Flanagan D *et al*. *National seasonal influenza vaccination survey for 2012-13 influenza season in EU/EEA (provisional data*. 2013:2013:1–153. June 2014. 2014;(November.

37   England Public Health. Flu plan. Winter 2015/2016.. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526143/Flu_Plan_Winter_2015_to_2016superseded.pdf.

38 Pebody RG, Mølbak K. Importance of timely monitoring of seasonal influenza vaccine effectiveness. *Eurosurveillance* 2016;21:2–4.

39 Kissling E, Nunes B, Robertson C, *et al*. I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? *Eurosurveillance* 2016;21.